Avian Influenza Vaccine Market Size Valued at USD 140.0 Million in 2021

According to Precision Business Insights (PBI) latest report the global avian influenza vaccine market is expected to be worth USD 145.7 million in 2022, growing at a 4.2% CAGR from 2022 to 2028. Global Avian Influenza Vaccine Market is segmented into the following types: Strain Type (Type H9, Type H7, Type…

According to Precision Business Insights (PBI) latest report the global avian influenza vaccine market is expected to be worth USD 145.7 million in 2022, growing at a 4.2% CAGR from 2022 to 2028. Global Avian Influenza Vaccine Market is segmented into the following types: Strain Type (Type H9, Type H7, Type H5, Others), Vaccine Type (Live Recombinant Vaccines, Inactivated Vaccines, Combination Vaccines), By Application (Duck & Goose, Chicken, Others) and Geography (North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa) Forecast to 2028. Key player’s profiles in the Avian Influenza Vaccine market report are Boehringer Ingelheim International GmbH (Germany), Guangdong Wenshi Dahuanong Biotechnology Co., Ltd (China), Ceva (US), Yebio Bioengineering Co., Ltd (China), Zoetis (US), FATRO S.P.A. (Italy), CAVAC (South Korea), Tianjin Ringpu Bio-Technology Co., Ltd (China), PT Japfa Comfeed Indonesia Tbk (Indonesia), Chengdu Tech-bank Biological Products Co., Ltd (China), Merck Animal Health (US), Medion (Indonesia), Avimex Animal Health (Mexico). An increase in the prevalence of bird flu, rising demand for poultry meat consumption, and an increase in the number of government and private sector initiatives to improve the animal healthcare industry are some of the factors that will likely boost the growth of the avian influenza vaccines market during the forecasting period. Furthermore, the players are focusing on acquisition to maintain the growth in the market In August 2017, Merck Animal Health announced the plans to purchase a new manufacturing facility in Austria. With this purchase, the company intended to expand its global vaccine manufacturing capacity.

H5 Strain Segment is Dominate the Avian Influenza Vaccine Market

Based on strain type, the global avian influenza vaccine market is segmented into type H9, type H7, type H5, and Others. H5 is the most common virus strain segment and holds most of the market share in the global influenza vaccine market. The outburst was caused by a strain of avian influenza virus called H5N1, which affected masses of chickens as well as other birds. Moreover, market players are focus one the development of advanced vaccines for H5 strain to meet the market needs. For instance, in October 2015, Boehringer Ingelheim developed Animal Health has launched a new vaccine Volvac B.E.S.T. AI + ND(Baculovirus Expression System Technology)was developed specifically to improve control ofAvian Influenza and Newcastle Disease.

North America Leads Avian Influenza Vaccine Market

North America held the largest growth rate in the global avian influenza market and the market is anticipated to grow at a significant growth rate over the forecast years due to burgeoning meat and poultry industries, rising animal health spending, and the existence of a high number of veterinary institutions in the region. In 2017, the US exported 3.7 million metric tonnes (MT) of chicken and poultry variety meats, according to the North American Meat Institute. It was projected to be worth USD 4.5 billion. Furthermore, increasing government funding for raising knowledge about avian influenza viruses and enhancing vaccination efficiency is favorable impacting the market growth.

Request sample report at: https://precisionbusinessinsights.com/request-sample?product_id=37365

Strategic New Product Launches, Mergers, Acquisitions and Agreements are the key strategies adopted by market players

Global Avian Influenza Vaccine market further reveals that the key players increasingly adopting strategies such as launch of newer products, product launches, and long-term alliance to improve market revenue share and gaining significant geographic presence across the region. For instance,

  • In August 2017, Merck Animal Health announced the plans to purchase a new manufacturing facility in Austria. With this purchase, the company intended to expand its global vaccine manufacturing capacity.
  • In March 2016, Zoetis announced that the US Department of Agriculture (USDA) granted the company a conditional license for Avian Influenza Vaccine, H5N1 Subtype, and Killed Virus.

Detailed Segmentation

Based on the strain type:

  • Type H9
  • Type H7
  • Type H5
  • Others

Based on the Vaccine type:

  • Live Recombinant Vaccines
  • Inactivated Vaccines
  • Combination Vaccines

Based on the Application:

  • Duck & Goose
  • Chicken
  • Others

Based on Geography:

  • North America
  • Europe
  • Asia Pacific
  • MEA
  • Latin America

Contact:
Mr. Satya
Precision Business InsightsTM | Toll Free: +1 866 598 1553
Email: sales@precisionbusinessinsights.com
Kemp House, 152 – 160 City Road, London EC1V 2NX
Web: https://precisionbusinessinsights.com/ | D U N S® Number: 852781747

ASIA PACIFIC OFFICE

Precision Business Insights, MIG 366, SAI PLAZA, 1st Floor, KPHB Colony, Hyderabad - 500072

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX